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Abstract
Background: Megalin is a large endocytic receptor with relevant functions during development and adult life. It is expressed
at the apical surface of several epithelial cell types, including proximal tubule cells (PTCs) in the kidney, where it internalizes
apolipoproteins, vitamins and hormones with their corresponding carrier proteins and signaling molecules. Despite the
important physiological roles of megalin little is known about the regulation of its expression. By analyzing the human
megalin promoter, we found three response elements for the peroxisomal proliferator-activated receptor (PPAR). The
objective of this study was to test whether megalin expression is regulated by the PPARs.
Methodology/Principal Findings: Treatment of epithelial cell lines with PPARa or PPARc ligands increased megalin mRNA
and protein expression. The stimulation of megalin mRNA expression was blocked by the addition of specific PPARa or
PPARc antagonists. Furthermore, PPAR bound to three PPAR response elements located in the megalin promoter, as shown
by EMSA, and PPARa and its agonist activated a luciferase construct containing a portion of the megalin promoter and the
first response element. Accordingly, the activation of PPARa and PPARc enhanced megalin expression in mouse kidney. As
previously observed, high concentrations of bovine serum albumin (BSA) decreased megalin in PTCs in vitro; however, PTCs
pretreated with PPARa and PPARc agonists avoided this BSA-mediated reduction of megalin expression. Finally, we found
that megalin expression was significantly inhibited in the PTCs of rats that were injected with BSA to induce
tubulointerstitial damage and proteinuria. Treatment of these rats with PPARc agonists counteracted the reduction in
megalin expression and the proteinuria induced by BSA.
Conclusions: PPARa/c and their agonists positively control megalin expression. This regulation could have an important
impact on several megalin-mediated physiological processes and on pathophysiologies such as chronic kidney disease
associated with diabetes and hypertension, in which megalin expression is impaired.
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Introduction
Megalin/LRP2 is a large membrane glycoprotein that belongs
to the low-density lipoprotein receptor (LDLR) family, which
includes LDLR, LRP8 (apolipoprotein E receptor 2) very low-
density lipoprotein receptor, LDLR-related protein 1 (LRP1) and
LRP1B [1]. This multiligand endocytic receptor is expressed on
the apical membrane of several epithelial cells, including those of
the kidney proximal tubule cells (PTCs), lung, thyroid [2],
gallbladder [3] and neuroepithelium [4,5]. The ectodomain of
megalin/LRP2 is very large and is responsible for ligand binding.
In contrast, the cytoplasmic domain of the receptor is relatively
small and contains three NPXY motifs, which have been suggested
to regulate its endocytic activities [6]. In addition, the megalin
cytoplasmic domain determines the apical localization of the
receptor [7] and can be phosphorylated by glycogen synthase
kinase 3(GSK3), an event that regulates megalin recycling and cell
surface availability [8].
Megalin’s functions cover a broad spectrum and include
processes that are critical during development [4,5,9,10,11] and
adult life and are impaired in several pathologic conditions that
compromise the kidney and the central nervous system [12,13,14].
In addition, it has been recently suggested that megalin could have
roles in regeneration processes in both peripheral and central
nervous systems as well as in kidney [15,16,17,18,19,20]. One of
the best studied systems of megalin function is the proximal tubule,
where the receptor is able to recover and internalize several
molecules, including complexes of vitamin A, B12 and D, along
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angiotensin II (and I-VII) [23,24], insulin [25] and albumin [12].
Megalin expression is compromised in kidney disease associated
with diabetes [26,27] and other conditions, such as aging [28].
However, the molecular mechanisms underlying downregulation
of this receptor remain obscure. Additionally, little is known about
the transcriptional mechanisms regulating the physiological
expression of the megalin gene. Previous studies have indicated
a positive regulatory role of cyclic AMP, retinoic acid and vitamins
A and D in the expression of megalin in cell culture [29,30].
Angiotensin II and insulin have also been reported to be involved
in the regulation of megalin expression in opossum proximal
tubule cells (OK) [31]. Finally, although the mechanism is unclear,
high concentrations of albumin significantly reduced the expres-
sion of megalin in PTCs in vitro [32].
Peroxisome proliferator-activated receptors (PPARs) are tran-
scription factors belonging to the nuclear receptor superfamily, for
which three isoforms (a, b/d and c) that are encoded by separate
genes have been described [33]. PPARs form active heterodimers
with the 9-cis-retinoid X receptor (RXR) and bind to character-
istic DNA sequences, the PPAR-responsive elements (PPREs) that
are located in the promoters of their target genes [34]. Fatty acids
and their oxidized metabolites have been proposed to be natural
PPAR ligands [35,36,37]. Moreover, synthetic ligands for PPARa
and PPARc such as fibric acid and thiazolidinediones, have
positive effects in human diseases, including type 2 diabetes,
metabolic syndrome, obesity and insulin resistance [38]. It is also
known that PPARs regulate the expression of some LDLR family
receptors, with LRP1 expression induced by PPARc [39] and
VLDL-R expression regulated by PPARa [40].
Megalin is highly expressed in a pattern similar to the three
PPAR subtypes in the kidney [41,42] and in PTC lines [43]. In
addition, both PPARa and PPARc agonists have renoprotective
actions that are independent of their systemic roles related to
metabolic control [38]. A long-term study of human patients with
type 2 diabetes showed that treatment with the PPARa agonist
fenofibrate significantly reduced albuminuria [44], which could
be potentially related to megalin function in the kidney, including
its function as an albumin receptor. In addition, the PPARa
agonists gemfibrozil and fenofibrate were able to reduce kidney
hypertrophy and fibrosis associated with diabetic nephropathy in
two different diabetic animal models [45,46]. Furthermore, the
beneficial effect of gemfibrozil on the kidney was shown to be
independent of the lipid-lowering effect of the drug [45]. The
dual PPARa/c agonists, JTT-501 [47] and compound 3q [45],
are also renoprotective agents in both mouse and rat diabetic
models. Moreover, in diabetic patients and diabetic animal
models, which exhibit reduced megalin expression [26,27], it has
been shown that several PPARc agonists decreased albuminuria
[45,47,48,49,50,51,52]. It has also been reported that the
treatment with the PPARc agonist pioglitazone increased tubular
cell albumin uptake in vitro [43]. However, in these studies, the
mechanisms by which the synthetic PPAR agonists reduced the
albuminuria and promoted albumin uptake in PTCs were not
completely clear and likely involved glomerular as well as tubular
effects.
In this study, we tested the hypothesis that megalin expression is
regulated by PPARs. We found three consensus PPREs in the
human megalin promoter. In addition, we show evidence that
PPARa, PPARc and their corresponding ligands induce megalin
expression at the mRNA and/or protein level in cell lines and in
the kidney in vivo. Using in vitro PTC models of BSA-induced
downregulation of megalin expression, we demonstrate that
treatment with either PPARa or PPARc agonist ameliorates the
reduction in megalin expression. This protective effect was also
observed when PPARc agonists were used in vivo. Overall, our
findings suggest that PPARs and their agonists could be critical
regulators of megalin expression in various pathophysiological
conditions, including chronic renal disease.
Results
The presence of PPREs in the megalin promoter and the
participation of PPARa and PPARc, but not PPARb/
dagonists in megalin expression
The analysis of the human megalin promoter sequence
(NC_000002.11) using MatInspector revealed the presence of
three putative PPREs, located at 2696 bp (AGGTCACAGAT-
CTC), 22150 bp (GCTGCTACAGTGAAAGGGCACAC) and
22800 bp (TGGCTTCTGGGGCAATGGT) relative to the
transcriptional start site (Fig. 1). This finding prompted us to
determine whether megalin expression responds to distinct PPAR
agonists in in vivo and in vitro models.
First, we determined baseline megalin expression levels in LLC-
PK1 cells, an epithelial cell line derived from kidney proximal
tubule, and in BN cells, a cell line derived from rat yolk sac. The
expression of the three PPAR subtypes has previously been
documented in kidney [41,42] and proximal tubule cell lines,
including LLC-PK1 cells [53,54,55]. Additionally, we confirmed
the expression of PPARa, b and c in BN cells by RT-PCR (Fig.
S1). Next, cells were treated with varying concentrations of either
WY 14643 (a potent PPARa agonist), GW 610742 (a PPARb/d
agonist), telmisartan (an angiotensin II type-1 receptor (AT1)
blocker that is also a PPARc modulator [56,57]) and rosiglitazone
(a synthetic agonist for PPARc). After treatment for 24 h, cells
were lysed, and megalin and b-tubulin protein levels were
determined by western blot. Treatment with WY 14643 led to a
dose-dependent increase in the expression of megalin, which was
significant starting at concentrations of 50 mM in both cell lines,
and a reduction in expression towards control levels at higher
doses of 200 mM (Fig. 2A). In contrast to the effect of the PPARa
agonist WY 14643, agonists for PPARb/d did not affect megalin
expression in either cell line (Fig. 2B). The effect of PPARc
agonists was evaluated using rosiglitazone (Fig. 2C) and telmi-
sartan (Fig. 2D). Both agonists were able to significantly induce the
expression of megalin in BN and in LLC-PK1 cells.
Endogenous megalin mRNA expression responses to
PPARa and PPARc agonists and antagonists
We determined if PPARa, PPARc and their ligands could
induce megalin expression at a transcriptional level by qRT-PCR.
When LLC-PK1 cells were treated with agonists (100 mMW Y
14643 or 1 mM rosiglitazone) for 24 h, megalin mRNA levels were
significantly induced. In contrast, when cells were only incubated
with an antagonist for either PPARa (GW 6471) or PPARc (GW
9662), the expression of megalin was significantly reduced
compared to the control condition, indicating that an important
aspect of the regulation of basal megalin transcription may be
mediated by PPARa/c ligands, such as fatty acids, present in the
serum. Interestingly, when cells were pre-incubated with the
PPARa and PPARc antagonists, the effects of the agonists WY
14643 and rosiglitazone were inhibited (Fig. 3A, C). As known
PPAR target genes, we determined the expression of Acox and
caveolin 1 after stimulation of PPARa and PPARc, respectively
(Fig. 3B, D).The expression of both genes was altered as expected
after treatment with the appropriate agonists/antagonists. These
results suggest that both PPARa and PPARc nuclear receptors are
involved in the activation of megalin gene transcription.
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Because PPARs agonists induced the expression of megalin in
cell culture, we evaluated whether these compounds were also able
to increase megalin expression in vivo in mice. BALB/c mice were
treated with the PPARa ligands ciprofibrate and WY 14643 or the
PPARc ligands rosiglitazone and telmisartan (for details, see Table
S3). Activation of PPARa with ciprofibrate significantly induced
the expression of megalin in the mouse kidney at the protein level,
as measured both by western blot (Fig. 4A, B) and by
immunohistochemistry (Fig. 4C, D). In contrast, this treatment
did not modify the expression of megalin at the mRNA level
(Fig. 4E) although the PPARa activator treatment did effectively
alter expression of the target gene Acox (Fig. S2A). Treatment
with WY 14643 also upregulated the expression of Acox mRNA
(Fig. S2A), but similar to ciprofibrate treatment, was unable to
induce megalin expression at the mRNA level (Fig. S2B).
However, the expression of megalin protein, as determined by
western blot, was significantly increased by WY 14643 (Fig. S2C,
D). In contrast, treatment with the PPARc activator rosiglitazone
significantly increased the expression of megalin at both the
protein and mRNA levels (Fig. 5A–E). Similar to rosiglitazone,
treatment with Telmisartan, a partial PPARc agonist, resulted in
the induction of megalin at protein level in mice (Fig. S3A, B) and
in the kidney of rats, as determined by both IHQ (Fig. S3C, D)
and qPCR (Fig. 9A).
Activation of a megalin promoter construct containing
the putative PPRE, located at -696 bp relative to the
transcription initiation, by PPARa and its agonist in a
Luciferase/b-galactosidase Reporter Assay
We next investigated whether a luciferase reporter gene
construct containing an 800-bp region of the human megalin
promoter sequence and the first PPRE was able to respond to
PPAR transcription factors and their ligands (Fig. 6A). BN cells
expressing the megalin promoter construct were able to induce
luciferase expression by 30-fold when coexpressing exogenous
PPARa and by nearly 50-fold when they were also incubated
with the PPARa agonist, WY 14643 (Fig. 6B). In contrast,
overexpression of PPARc with or without its ligands (rosiglita-
zone or telmisartan) was unable to induce luciferase expression
(Fig. 6C). Similar results were obtained when LLC-PK1 cells
were used (data not shown). These results suggest that the first
PPRE of the human megalin promoter is targeted by PPARa,b u t
not PPARc.
Binding of PPARa-RXRa and PPARc-RXRa heterodimers
to PPREs identified in the megalin promoter region
We tested the binding ability of the three PPRE consensus sites
in the human megalin promoter using electrophoretic mobility
shift assay (EMSA) reactions (Fig. 1). For the first PPRE, located at
2696 to 2683, we observed specific binding of a PPARa-RXRa
heterodimer. In contrast, we did not find any specific binding for
PPARc because an excess of either the wild-type or the mutant
unlabeled oligomers were able to displace the
32P-end-labeled
DNA from its binding to the heterodimer (Fig. 7A). These results
are in agreement with the promoter activation assays, which
indicated that PPARa, but not c, was able to activate the PPRE
present in this promoter region. PPARc agonists activated megalin
expression both in vivo and in vitro; thus, we hypothesized that the
other two PPREs at positions – 2800 and -2150 might be able to
bind the PPAR-RXRa protein complexes. In accordance with this
hypothesis, both PPARa and PPARc specifically bound to the
labeled oligomer that corresponded to the -2150 promoter region
(Fig. 7B, C). This binding could be competed away by a 20- to 50-
fold increase of the wild-type, but not the mutant, PPRE oligomer.
PPARa binding to the -2800 PPRE region was somewhat weak in
our experimental conditions but still could be displaced by an
excess of the appropriate unlabeled oligomer. However, the
binding of PPARc to this region was clear and specific. We did not
detect binding of PPARb/d-RXRa heterodimers to any of the
sequences analyzed (data not shown), which is in agreement with
our data demonstrating that treatment with PPARb agonist did
not increase megalin expression (Fig. 2). Overall, these results
indicate that PPARa and PPARc bind to multiple PPREs in the
megalin promoter, which supports our observations of activated
megalin expression in the various model systems treated with
PPAR agonists.
Figure 1. Putative PPAR consensus sites in the human megalin promoter. Nucleotide numbering is labeled relative to the transcription start
site (nt +1, arrow). Putative PPAR responsive-elements (PPREs) were located by MatInspector (www.genomatix.de).
doi:10.1371/journal.pone.0016794.g001
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albumin: the role of PPARa and PPARc agonist
treatments
Reduced megalin immunoreactivity has been previously
described in diabetic rats with albuminuria [26]. In addition, high
doses of BSA were associated with a decrease in megalin
expression in PTCs in vitro, but the mechanism for this observation
was not determined [32]. Based on these studies, we reasoned that
the treatment of LLC-PK1 cells with high concentrations of BSA
combined with the effect of PPARa and PPARc agonists on
megalin expression would be a good model to initially test for a
protective role of these nuclear receptors on megalin expression.
We found that megalin expression was significantly reduced in
cells that were exposed to BSA concentrations over 10 mg/ml
(Fig. 8A), similar to previously published data [32]. When cells
were exposed to agonists for PPARa (WY 14643) or PPARc
(rosiglitazone), megalin mRNA levels significantly increased (Fig. 3,
Fig. 8B–C). Interestingly, when the cells were treated with PPAR
agonists and BSA (10 mg/ml) simultaneously, both agonists were
able to significantly counteract the inhibitory effect of BSA on
megalin expression.
We next moved to an in vivo model; we induced proteinuria in
healthy rats by daily administration of 2 g BSA for one week,
which resulted in downregulation of megalin expression, similar to
the in vitro observations. To test whether activation of PPARc was
able to prevent the reduction of megalin in kidney, three groups of
four animals received vehicle, telmisartan or rosiglitazone for four
days. During this ‘‘pretreatment’’ condition, the expression of
megalin was determined by qPCR and found to be significantly
increased in the kidneys of the animals receiving telmisartan or
rosiglitazone compared to the controls (Fig. 9A). In parallel, four
other groups of animals, including two controls pretreated with
vehicle, started receiving daily injections of BSA (or saline as
control) for 7 days to induce tubulointerstitial damage as
previously described [58,59,60]. Before and after the BSA
administration, renal function parameters were determined.
Figure 2. Megalin protein levels are increased in BN and LLC-PK1 cultured cells upon exposure to PPARa and PPARc agonists, but
not PPARb agonists. (a) BN cells (600,000 cells/well) and LLC-PK1 cells (500,000 cells/well) were treated with different concentrations of the PPARa
agonist WY 14643, (b) the PPARb agonist GW 610742, and the PPARc agonists (c) rosiglitazone and (d) telmisartan for 24 h in 0.5% FBS in DMEM.
Cells were lysed and the expression of megalin and the loading control, b-tubulin, was determined by western blot. The bands in the blots were
quantified by densitometry, and the results were plotted as the ratio of megalin/b-tubulin for each condition. Statistically significant differences
compared to the control (DMSO) are indicated as *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0016794.g002
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(Table 1), but rats in the BSA-treated group developed significant
proteinuria (Fig. 9B, Table 1) that was significantly lower in the
animals treated with rosiglitazone, indicating a protective role for
PPARc in this experimental condition (Fig. 9B). Megalin mRNA
levels were also significantly lower in the BSA-treated animals
receiving vehicle (Fig. 9C); however, in the rats receiving
telmisartan the negative effect of BSA on megalin expression
was avoided, and in the animals receiving rosiglitazone the effect
of BSA was partially neutralized. In both cases megalin mRNA
expression were maintained at levels similar to the control animals
(saline) (P=0.81, control + saline vs. Telmisartan + BSA; P=0.38,
control + saline vs. rosiglitazone +BSA). Moreover, in the
Telmisartan + BSA group, megalin mRNA was significantly
upregulated compared the control + BSA group; a similar, but not
significant, tendency was observed in the rosiglitazone + BSA
group (P=0.1, vs. control + BSA). The effects of the BSA
injections and PPARc agonist treatments were also established by
morphological examination. The BSA-treated animals exhibited
marked tubular lesions within the proximal and distal tubules,
including epithelial flattening, tubular dilatation, intraluminal
proteinaceous casts and interstitial infiltration of mononuclear
cells, without evidence of fibrosis. In addition, a clear reduction in
immunoreactive renal megalin located at the luminal pole of
proximal cells was evident in BSA-treated animals compared to
control animals, especially in the tubules showing intraluminal
proteinaceous casts (Fig. 9D). Consistent with the alterations in
mRNA levels, megalin immunoreactivity was less decreased in the
BSA-treated animals receiving PPARc agonists compared to the
BSA-treated animals receiving vehicle (Fig. 9D). Overall, these
results indicate that the reduction in megalin expression observed
in kidneys exposed to high doses of BSA is partially, but
significantly, prevented by treatment with PPARc agonists.
Discussion
The fundamental role of megalin in kidney and in development
is clearly demonstrated by the phenotype of megalin knockout
mouse models [4,5,61,62]. The absence of megalin expression in
the kidney is associated with the urinary loss of ligands, including
albumin and low molecular weight proteins such as vitamin D-
binding protein and retinol-binding protein. Kidneys of megalin
Figure 3. PPARa and PPARc agonists or antagonists regulate megalin mRNA expression in LLC-PK1 cells. (a, b) LLC-PK1 cells were
treated with 100 mM WY 14643 (PPARa agonist), 10 mM GW 6471 (PPARa antagonist) or both drugs for 24 h. Megalin and Acox mRNA levels were
determined by qPCR, and values were normalized to the housekeeping gene actin (n=4). (c, d) LLC-PK1 cells were exposed to 1 mM rosiglitazone
(PPARc agonist), 10 mM GW 9662 (PPARc antagonist) or both drugs for 24 h. Megalin and caveolin 1 mRNA levels were detected by qPCR, and values
were normalized to the signal from the housekeeping gene actin (n=4). Results are expressed as means 6 standard deviation (SD). Statistically
significant differences compared to the control (DMSO, vehicle) are indicated by *P,0.02, **P,0.01, ***P,0.001. Statistically significant differences to
the agonist alone are indicated by
#P,0.001.
doi:10.1371/journal.pone.0016794.g003
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compartments of PTCs, including clathrin-coated pits and apical
recycling compartments [61]. In addition, it has recently been
suggested that megalin expression is decreased in the kidneys of
old rats [28], which could potentially affect the renal functions in
which megalin is involved. Moreover, there are pathological
conditions, such as Dent’s Disease and Lowe Syndrome, in which
megalin expression is functionally compromised [14,63,64].
However, despite the important roles of the megalin receptor,
there are few studies that have investigated the mechanisms that
control its expression.
In this study, we have shown for the first time, using both in vitro
and in vivo models, that megalin expression is induced by PPARa
and PPARc agonists at the mRNA and/or protein levels. We
found that specific antagonists for PPARa and PPARc disrupted
the activation effect of WY 14643 and rosiglitazone, respectively,
Figure 4. PPARa agonists regulate megalin expression in vivo in mice. BALB/c mice (n=3–5/per group) received ciprofibrate (200 mg/kg/
day) or vehicle for 1 week. (a) Kidney extracts were used to determine megalin protein levels by western blot, with b-tubulin used as loading control.
(b) The bands in the blots were quantified by densitometry, and the results were plotted as the ratio of megalin/b-tubulin for each condition. (c)
Immunohistochemical staining for the megalin cytoplasmic domain in kidney sections (cortex) showed increased staining for megalin in ciprofibrate–
treated mice compared to control mice. Bar=100 mm. (d) The megalin-immunostained area was significantly increased in the ciprofibrate group
compared to the control group as measured by morphometric analysis. The quantification of the megalin-stained area is shown as mm
2.( e) Megalin
mRNA expression was determined from kidney RNA by qPCR. Data are expressed as means 6 SD. *P,0.05 vs. control, **P,0.0001 vs. control.
doi:10.1371/journal.pone.0016794.g004
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of megalin expression. In addition, several lines of evidence
support the role of both nuclear receptors in the activation of
megalin expression. First, overexpression of PPARa activates
expression of a luciferase gene under the control of a portion of the
human megalin promoter containing one PPRE. Second, the
effect of telmisartan, which binds directly to PPARc [65].
Moreover, we showed that PPARa and PPARc heterodimers
containing RXR bind to at least two of the three PPREs present in
the human promoter of megalin, which is a potential mechanism
for the activation of megalin expression observed at the
transcriptional level in our animal and cellular models.
We tested the hypothesis that megalin is a novel PPARa and
PPARc target gene in order to determine whether these nuclear
Figure 5. PPARc agonists regulate megalin expression in vivo in mice. BALB/c mice (n=4–6/per group) received rosiglitazone (20 mg/kg/
day) or vehicle for 10 days. (a) Kidney extracts were used to determine megalin protein levels. b-tubulin was used as loading control. (b) The bands in
the blots were quantified by densitometry, and the results were plotted as the ratio of megalin/b-tubulin for each condition. (c)
Immunohistochemical staining of megalin in kidney sections (cortex) showing increased immunostaining for megalin in rosiglitazone-treated
mice compared to control mice. Renal tissue was immunostained using an antibody that detects the megalin cytoplasmic domain. Bar=100 mm. (d)
The megalin-immunostained area was significantly increased in the rosiglitazone group compared to the control group as measured by
morphometric analysis. The graph shows the quantification of the megalin-stained area in mm
2.( e) Megalin mRNA levels were determined by qPCR.
Data are expressed as means 6 SD. *P,0.05 vs. control, **P,0.0001 vs. control.
doi:10.1371/journal.pone.0016794.g005
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conditions in which there is reduced megalin expression using in
vitro and in vivo methodologies. Our strategy was based on the data
previously published by Caruso-Neves et al. [32], which showed
that LLC-PK1 cells incubated with high concentrations of BSA
have a significant reduction in megalin at both the mRNA and
protein levels. Although the mechanisms involved in the BSA-
mediated reduction of megalin were not completely clear, this
study proposed that megalin normally has a protective role in
PTCs based on its direct association to PKB/AKT in conditions
that are associated with high concentrations of albumin and
because the severely reduced megalin expression levels were
correlated with the induction of PTC apoptosis [32]. A similar
situation could occur in vivo if the barrier function of the
glomerulus was disrupted, resulting in excess filtration of albumin
and induction of renal damage. Interestingly, we found that the
pretreatment of LLC-PK1 cells with either PPARa or PPARc
agonists prevented the drastic reduction of megalin using similar
Figure 6. The first PPRE of the megalin promoter is activated by PPARa, but not PPARc. (a) Schematic of the construct used to analyze
megalin promoter activity. (b) BN cells (6610
4 cells) were seeded in 24-well plates in triplicate. The cells were transfected 24 h later with the megalin
promoter construct (2800 meg-Luc) and a b-galactosidase vector (pCMVb). Cotransfections were performed by adding either PPARa or PPARc
cDNAs. After 24 h, the transfected cells were treated with specific agonists for the PPARs and incubated for an additional 24 h prior to assaying the
luciferase activity. Cells expressing the megalin promoter construct were able to increase luciferase activity 30-fold when PPARa was overexpressed
and nearly 50-fold when in addition to PPARa, cells were treated with 100 mM WY 14643. (c) In contrast, overexpression of PPARc with or without the
corresponding ligands and treatment with rosiglitazone or telmisartan was unable to induce luciferase expression. Data are expressed as means 6
SD. *P,0.05 vs. the 2800 meg-Luc control.
doi:10.1371/journal.pone.0016794.g006
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next tested whether megalin expression in PTCs in vivo could also
be downregulated by an excess of filtered albumin and whether
expression could be recovered by PPARc agonists. Our results
demonstrated that treatment with PPARc agonists circumvented
the significant reduction of megalin in PTCs from BSA-injected
rats and also reduced the proteinuria that had developed in these
animals. These observations may provide a mechanistic context to
the known protective roles of PPARa/c in kidney diseases, such as
diabetic nephropathy, which is associated with proteinuria and
compromised expression of megalin. In addition, recent studies
indicate that megalin expression is reduced in conditions
associated with proteinuria. For example, megalin expression
was reduced in the Ren2 rat, a model used for studying
hypertension and metabolic syndrome [66]. Treatment of Ren2
rats with a b1-antagonist blocker to reduce the secretion of renin
improved the reabsorption of albumin and LMW proteins by the
PTCs and restored megalin expression levels. Our data suggest
that treatment with the PPARc partial agonist/AT1 antagonist
telmisartan would also have a beneficial effect in this model,
Figure 8. PPARa and PPARc agonists have a protective role against BSA-induced megalin downregulation in cultured PTCs. LLC-PK1
cells were seeded and used 2 days after confluence was reached. Before use in experiments, cells were cultured in medium depleted of serum for
16 h. Each condition was assayed in triplicate. (a) Cells were incubated with different concentrations of BSA for 24 h. Megalin mRNA expression was
determined by qPCR. At concentrations of 10 mg/ml, BSA induced a significant reduction in megalin mRNA expression (n=3). (b, c) LLC-PK1 cells
were pretreated with 100 mM WY 14643 (PPARa agonist), 1 mM rosiglitazone (PPARc agonist) or vehicle for 1 h prior to 20 mg/mL BSA exposure,
which was maintained for 24 h. Megalin mRNA levels were determined from cellular RNA extracts by qPCR. Values were normalized to the expression
of the housekeeping gene of actin (n=3–4). Results are expressed as means 6 standard deviation (SD). Statistically significant differences are
indicated as *P,0.05, **P,0.01.
doi:10.1371/journal.pone.0016794.g008
Figure 7. Binding of PPAR/RXRa heterodimers to the PPREs in the human megalin promoter. EMSAs were performed with in vitro
translated RXRa plus PPARa or PPARc using probes for the wild-type (wt) PPREs of the human megalin promoter. The competition analyses were
performed with a 20- or 50-fold excess of the wt or mutated probes. (a) 2700 bp, (b) 22150 bp and (c) 22800 bp. PPARa bound to all the sites,
whereas PPARc bound specifically to the 22150 and 22800 bp sites.
doi:10.1371/journal.pone.0016794.g007
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angiotensin II with hypertensive conditions [31].
Similar to PPARc agonists, treatment with PPARa agonists has
been linked to a reduction in proteinuria [46] and to the regulation
of the renin-angiotensin system, with a reduction of AT1 and the
induction of AT2 expression in the kidney [67]. Furthermore, it
has been shown that renal disease, including albuminuria, is more
severe in diabetic mice that are genetically deficient for PPARa
than in wild-type mice [68]. Although we did not test PPARa
agonists in our protein overload model in rats in vivo, we did
demonstrate the protective role of PPARa agonists in an in vitro
model of PTCs that were incubated with high doses of albumin
and showed that PPARa agonists regulate megalin expression in
vivo in mice. Interestingly, in mice, the hypolipidemic drugs
ciprofibrate and WY 14643 exerted their effects at the level of
megalin protein expression and did not increase megalin mRNA,
in contrast to the upregulation of megalin mRNA that was
induced in our cell culture model after a similar treatment. These
somewhat contradictory results are not necessarily unexpected
because differential activity of PPARa and its ligands on the
expression of various genes has been reported, and it depends on
the species of the analyzed gene [69,70] and of the PPARa itself
[70]. For example, in human, but not in rodent cells, the
expression of the gene encoding for hydroxysteroid sulfotransfer-
ase (sult2a1) is induced in a PPARa dependent manner by
ciprofibrate and WY 14643 [69]. In mice, the expression of the
same enzyme is induced by WY 14643 in transgenic animals
expressing human PPARa, but not in wild-type mice, indicating
that only the human PPARa is able to activate the PPREs of the
sult2a1 gene. In our study, however, it is unlikely that the
differential response of megalin mRNA expression observed in the
mice is due to the PPARa species. Our experiments that tested the
activation of the human megalin promoter by luciferase reporter
assay and the EMSAs, which used human megalin probes, were
performed with mouse PPARa. Moreover, the DNA-binding
domains of human and mouse PPARa are completely homologous
[70], suggesting that they should bind with similar affinities to the
megalin PPREs. Another potential difference to consider is related
to the numbers and sequences of PPREs in the megalin promoters
of different species. Using Matinspector software (www.genomatix.
de), we found that human, mouse and rat megalin promoters have
different numbers and sequences of PPREs (data not shown). This
difference could contribute to the absence of an induction of
megalin mRNA expression by PPARa agonists in the mouse
kidney in vivo and should be further explored in future studies.
Nevertheless, although megalin mRNA expression was not
modified by the PPARa agonists ciprofibrate and WY 14643 in
vivo, megalin protein levels were increased. Both agonists have
been implicated in the regulation of the expression of several genes
encoding inflammatory molecules, proteins related to lipid
metabolism and transcription factors [71,72]; several of these
molecules could directly or indirectly affect megalin expression in
the whole animal. It is also possible that turnover of the megalin
protein is modified by PPARa agonists, leading to decreased
degradation. For example, ciprofibrate, via a PPARa -dependent
mechanism, has distinct roles in the expression of the HDL
receptor, SR-BI; ciprofibrate increases SR-BI protein levels
expression in murine and human macrophages [73] but reduces
Table 1. Physiological data of BSA injected rats.
Vehicle+ saline Vehicle + BSA Telmisartan + BSA Rosiglitazone + BSA
Body weight (g) Initial 193.0612 189.7610 183.365.0 187.066.1
Final 225.3618 234.767.4 213.7625 230.7614
Creatinine clearance (ml/min) Initial 0.8560.12 0.9360.04 1.0460.18 1.1660.07
Final 1.2160.31 0.9660.16 1.1660.24 1.2360.20
Proteinuria (mg protein/mg creatinine) Initial 9.7562.57 5.9662.03 5.6360.87 9.1660.99
Final 4.2463.95 73.27624.4
# 37.2267.7 25.58611.9
*
Serum creatinine (mg/dl) Initial 0.4760.06 0.4760.06 0.4060.00 0.4060.00
Final 0.4360.06 0.5060.00 0.4360.06 0.4060.00
Sprague-Dawley rats, were pretreated with Telmisartan (3 mg/k/day, n=4), Rosiglitazone (3 mg/k/day; n=4) or vehicle (in this case n=8) for 4 days. From day 5 to 11
the animals continued with the treatment and were, in addition, injected with sterile saline or BSA (2 g/Day) as indicated. Creatinine clearance, serum creatinine and
proteinuria were determined as described in Methods on the day 5 and 11 of the experiment.
#P,0.001 (vs Control + Saline);
*P,0.05 (vs Control + BSA).
doi:10.1371/journal.pone.0016794.t001
Figure 9. PPARc agonists have a protective role in BSA-induced tubulointerstitial damage, decrease proteinuria and prevent
downregulation of megalin. (a) The expression of megalin mRNA, determined by qPCR, in the kidneys of rats treated with telmisartan or
rosiglitazone for 4 days was increased significantly compared to the control (vehicle); *P,0.05 vs. control. (n=4 per group). (b) A separate group of
rats continued with the treatments for one week and simultaneously received daily injections of 2 g BSA or saline. Before (Initial) and after (Final) the
BSA injections, proteinuria (UV prot) was determined as explained in the Material and Methods. Pretreatment with agonists alone did not modify the
UV prot levels (comparison of all groups at Initial conditions); however, rosiglitazone decreased the proteinuria induced by the BSA injections.
#P,0.001 vs. final control + saline. *P,0.05 vs. final control + BSA. (c) At the end of the treatments, the expression of megalin was determined by
qPCR. BSA induced a significant downregulation of megalin mRNA compared to the control and both PPARc agonists maintained megalin mRNA
levels close to the control condition without BSA. **P,0.01 vs. control + saline, *P,0.05 vs. control + BSA. (d) Immunohistochemical staining for
megalin in kidney sections (cortex). In control animals, megalin protein is abundantly expressed in the apical pole of proximal tubule cells (PTCs),
whereas the BSA-treated animals exhibited a decrease in megalin immunostaining of the apical pole of PTCs, especially in areas where tubular
dilatation with intraluminal proteinaceous casts were evident (arrow). Kidneys from animals treated with BSA and PPARc agonists show a partial
recovery of megalin immunostaining along with the presence of less tubular damage. Representative figures from the different groups are shown.
Bar=100 mm.
doi:10.1371/journal.pone.0016794.g009
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fibrates activate different signaling pathways depending on ERK
phosphorylation status, activation of PKC and activation of PI3K/
AKT with inhibition of GSK3b [75,76,77,78]. Accordingly,
megalin expression is also regulated by signaling pathways
depending on ERK and PI3K in PTCs [31], its proteolytic
processing can be induced by PKC activation [79] and its cell
surface expression is upregulated upon GSK3b inhibition [8].
Taken together, these data could indicate that multiple mecha-
nisms may be operating to upregulate megalin expression in
PPARa agonist-treated mice. Whatever the mechanism, similar to
PPARc agonists, PPARa agonists could be used as protective
agents to reduce proteinuria and induce megalin expression.
PTC dysfunction with microalbuminuria is associated with early
states of diabetes [26] and precedes glomerular damage [26].
These observations reinforce that maintenance of megalin
expression, apical localization and trafficking in PTCs is critical
for avoiding albuminuria and the subsequent renal damage,
including inflammations and fibrosis. Furthermore, due to its role
in signaling molecule degradation, megalin expression is required
to negatively regulate the signaling of molecules involved in the
early and late stages of renal disease, including angiotensin II [23]
and leptin [22]; in addition to their other functions, these signaling
molecules are involved in the regulation of renal inflammation and
fibrosis and, for example, can induce the expression of TGFb and
Smad 2/3 activation [80,81,82,83]. Other physiologically relevant
roles of megalin include the tubular recovery of proteins such as
vitamin D binding protein and liver fatty acid binding protein
FABP1 [84]. Diabetic patients show an alteration in vitamin D
metabolism, with lower levels of 1,25-OH vitamin D [85], due to
an impairment in the activation of 25-OH vitamin D that occurs
in the PTC after megalin-mediated endocytosis of the DBP-
vitamin D complex. Moreover, treatment with PPARc agonist
pioglitazone reduced the urinary excretion of FABP1 in diabetic
patients [86], which again reinforces the role of the PPAR system
in the improvement of renal function through the activation of
megalin expression.
In addition to the kidney, there are many other systems in which
megalin function and expression are critical. During brain
development, megalin expression is essential because it controls
the sonic hedgehog and bone morphogenetic protein 4 signaling
pathways by regulating their availability [5]. In the adult, megalin
participates as an endocytic receptor in the gallbladder [3], blood-
brain barrier [87] and nervous system, where it is associated with
protection against neurodegeneration and with regenerative
processes [16,88]. Moreover, in all of these physiological systems,
PPARs function as protective agents [89,90,91,92,93]. Thus, the
significance of megalin/LRP2 expression in many organs is
evident, and, therefore, it is important to understand the molecular
and physiological regulation that controls expression of this the
receptor. With our study, we added an important contribution to
this field, showing that PPARa/c are involved in the control of
megalin expression. Our data indicate that, in addition to the
previously proposed functions and target genes of PPARa/c, the
regulation of megalin expression and availability should also be
considered an important role of the PPAR nuclear receptors.
Materials and Methods
Reagents
Dulbecco’s Modified Eagle’s Medium (DMEM), Minimum
Essential Medium Alpha Modification (aMem), glutamine, PMSF,
antipain, aprotinin, leupeptin, pepstatin, poly (dI-dC), BSA,
DMSO and Triton X-100 were purchased from the Sigma
Chemical Company (St. Louis, MO, USA). Fetal Bovine Serum
(FBS) was from Hyclone (South Logan, UT, USA). Trypsin and
Penicillin-Streptomycin were from Invitrogen/Gibco (Burlington,
ON, USA). Lipofectamine 2000, random primers and RNAse-
OUT were from Invitrogen (Carlsbad, CA, USA). The Luciferase
Reporter Assay and the TNT-coupled reticulocyte lysate system
were from Promega (Madison, WI, USA). WY 14643 (PPARa
agonist), GW 6471 (PPARa antagonist) and GW 9662 (PPARc
antagonist) were from Sigma. GW 610742 (PPARb/d agonist) was
a gift from GlaxoSmithKline (Research Triangle Park, NC, USA),
and rosiglitazone (PPARc agonist) was from Cayman Chemical
(Ann Arbor, MI, USA). BCA Protein Assay Reagent was from
Pierce (Rockford, IL, USA). RNA-Solv reagent was from Omega
Bio-Tek (Norcross, GA, USA). DNAseI, RevertAid M-MuLV
Reverse Transcriptase, BamHI and XhoI were from Fermentas
(Glen Burnie, MD, USA). Brilliant Sybr Green was from
Stratagene (La Jolla, CA, USA). Oligonucleotide primers were
obtained from Gene Link (Hawthorne, NY, USA). Telmisartan
(SAMERTAN) was from BAGO (Santiago, Chile). Rosiglitazone
(AVANDIA) and ciprofibrate (Estaprol) used for animal treat-
ments were from GlaxoSmithKline (Mississauga, ON, Canada)
and Sanofi Aventis (Amberes, France), respectively. Mouse
monoclonal antibody to b-tubulin was purchased from Chemicon
(Temecula, CA, USA). The polyclonal antiserum to recombinant
human megalin cytoplasmic domain (anti-MegT) was previously
described [7].The secondary antibodies for immunostaining and
PAP complex were purchased from ICN Biomedicals, Inc.
(Aurora, OH).
Plasmids and constructs
(PPRE)x3TK-Luc, pCMX-mPPARa, pCMX-mPPARb and
pCMXm PPARc were provided by Dr. R. M. Evans.
pCMX?mRXRa was provided by Dr. M.Ananthanarayanan,
and the -1500 pGL3-enhancer megalin promoter (21500 meg
prom) [94] was a gift from Dr. F. Lammert. TK-luc and pCMV-
bvectors were from Clontech (Palo Alto, CA, USA). The pGL3
enhancer vector was from Promega. The -800 luciferase megalin
promoter (2800 meg prom) was constructed as follows:
21500 meg prom was digested with BamHI and XhoI, and the
resulting 930-bp fragment containing 2830 to +100 (with +1
considered to be the transcriptional start site) of the megalin
promoter was subcloned into a TK-Luc plasmid previously
digested with BamHI and XhoI, which, therefore, lacked the
TK promoter.
Cell lines and treatments
LLC-PK1 and BN cells (both of which express endogenous
megalin) were cultured essentially as described [3] and maintained
at 37uCi n5 %C O 2. For testing PPAR agonists, BN and LLC-
PK1 cells were cultured overnight in medium containing 0.5%
FBS and then treated with agonists or vehicle (DMSO) for 24 h.
For the experiments in which the PPAR antagonists were used, the
cells were preincubated for 30 min before the addition of the
respective agonists. BSA treatment in LLC-PK1 was performed in
cells cultured overnight in medium depleted of serum. Then,
various concentrations of BSA were added to the cells for 24 h.
The treatments with PPAR agonists or the corresponding vehicle
were performed 1 h before adding albumin at 20 mg/ml and were
maintained for 24 h. At the end of the treatments, the cells were
used for detection of protein by western blot or for RNA isolation.
For western blots, the experiments were performed at least three
times (n=3), and for mRNA determination, each experimental
condition was performed in triplicate with n=3–4 independent
experiments.
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Cells were lysed in PBS containing 1% Triton X-100, 2 mM
PMSF, 1 mM pepstatin, antipain, 1 mM leupeptin and 0.3 mM
aprotinin. Kidney extracts were obtained as indicated below.
Equal amounts of protein from each extract were subjected to
SDS-PAGE under reducing conditions. The immunodetection of
megalin, tubulin or actin was determined as described [3,7].
Densitometric analysis was performed using the Gel Doc 2000 Gel
Documentation System and Quantity One version 4 software (Bio-
Rad, CA, USA). The signal generated by b-tubulin immunolabel-
ing was used for normalization.
Megalin mRNA quantification by real-time PCR (qPCR)
Total RNA was isolated using RNA-Solv and following the
manufacturer’s instructions. Total RNA (1 mg) was first digested
by DNAse I and then subjected to reverse transcription in a 20 ml
reaction mixture using random primers and RevertAid
TM M-
MuLV Reverse Transcriptase in the presence of RNAseOUT.
PCR reactions were performed using a 7500 Real-Time PCR
System (Applied Biosystems, Carlsbad, CA, USA). TaqMan gene
expression assay primers were used for mouse megalin, Acox and
GADPH (Applied Biosystems). For the other mRNAs, Brilliant
SybrGreen I (Stratagene) was used (see Table S1 for primers). All
primers were used at a final concentration of 300 nM. Analyses of
results were performed with the 7500 System Software.
Promoter and reporter assays
BN and LLC-PK1 cells were cotransfected with 300 ng of
2800 meg-Luc and 300 ng each of either PPARa or PPARc
cDNA. Control wells were supplemented with the same amount of
vector DNA such that the total amount of DNA added to each well
remained constant. All cells were also transfected with a b-
galactosidase vector (pCMVb) as an internal control for transfection
efficiency. On the second day, cells were treated with the appropriate
PPAR agonist for 24 h in their respective medium with 0.5% FBS.
Luciferase activity was assayed in a luminometer using the Luciferase
Reporter Assay System (Promega) according to the manufacturer’s
instructions. Luciferase activity was normalized for transfection
efficiency using the expression of b-galactosidase. Results are
expressed as the fold increase of activity over the control vector.
Electrophorectic mobility shift assays
Using the TNT-coupled reticulocyte lysate system (Promega),
cDNAs encoding mouse RXRa, PPARa, PPARb and PPARc
were transcribed and translated according to the manufacturer’s
instructions. Aliquots of the transcribed/translated extracts were
used for EMSAs. Reactions (2 ml) containing PPARa, PPARb or
PPARc alone or together with RXRa were added to 9 ml total
volume of binding buffer (10 mM Tris HCl, 50 mM NaCl,
0.5 mM dithiothreitol, 0.5 mM EDTA, 1 mM MgCl2,4 %
glycerol, 0.5 mg/ml poly (dI-dC) at 25uC for 15 min followed
by another 20 min incubation with 10 mCi of [c-
32P]ATP-labeled
oligonucleotide containing the putative human PPRE binding
sites. For competition assays, unlabeled wild-type or mutant
oligonucleotides were added to the reaction 15 min before the
addition of the probe. For probe details, see Table S2. The DNA-
protein binding complex was run on a 4% non-denatured
polyacrylamide gel in 0.256TBE at 220 V for 1.5 h. Gels were
autoradiographed using Kodak Biomax film.
Animals and experimental procedures
Animal protocols were carried out with approval from the
Review Board for animal studies at the Facultad de Ciencias
Biolo ´gicas and the Ethical Committee of the Facultad de
Medicina, Pontificia Universidad Cato ´lica de Chile (Approval
Certificate CE #020106) and according to the Guide for the Care
and Use of Laboratory Animals of CONICYT. Animals were
maintained at constant room temperature with a 12-h light/dark
cycle.
Ciprofibrate, WY 14643, rosiglitazone and Telmisartan
treatment in mice (see Table S3 for more details). The
kidneys were harvested and washed in PBS 24 h after finish-
ing the treatment protocols. One kidney was processed for
immunohistochemistry (as described below), and the other was
used for western blot and qPCR analyses. For western blots, one
kidney half was homogenized on ice in homogenization buffer
(PBS, 0.5% (v/v) Triton X-100, 2 mM PMSF, 1 mM pepstatin,
antipain, 1 mM leupeptin and 0.3 mM aprotinin) using a dounce
homogenizer; nuclear debris was removed by centrifugation at
3,0006g for 10 min at 4uC, and the supernatants were saved. For
qPCR assays, total RNA was isolated from the remaining kidney
half using RNA-Solv reagent (Omega-BioTek) according to the
manufacturer’s instructions.
Induction of tubulointerstitial damage and proteinuria in
Sprague-Dawley rats (see Table S4 for more details). After
treatments were finished, kidneys were removed for morphologic
and qPCR analyses from the rats while they were under anesthesia
(ketamine/xylazine). To determine the renal function levels,
animals were subjected to urine and blood collections. Urine
collections were performed in individual metabolic cages for 16 h,
during which time food was withheld to avoid fecal contamination,
but water was offered ad libitum. Functional damage was assessed
by the determination of serum creatinine levels and creatinine
clearance. Urine and plasma creatinine were assayed in a
Beckman Creatinine analyzer (Beckman Coulter, Fullerton, CA).
Creatinine clearance over 16 h was calculated according to the
standard formula C = UxV/P, where C is creatinine clearance, U
is creatinine urinary concentration, V is the urine flow rate per
minute and P is creatinine plasmatic concentration [95].
Tissue processing and immunohistochemical analysis
Renal tissue samples from the different groups (3 mm thick)
were fixed by immersion in Bouin’s solution for 24 h at room
temperature. The tissue was then dehydrated, embedded in
Paraplast Plus (Monoject Scientific, St. Louis, MO), serially
sectioned at 5-um thickness with a rotatory microtome, mounted
on glass slides and used for immunostaining. Immunostaining was
performed using an indirect immunoperoxidase technique [96,97]
to localize megalin in rat or mouse kidneys. Briefly, tissue sections
were dewaxed, rehydrated, rinsed in 0.05 M Tris-phosphate-saline
(TPS) buffer pH 7.6 and incubated with the primary antiserum
raised against megalin 1:120,000 overnight at 22uC. The
secondary antibody and the corresponding antiperoxidase (PAP)
complex were applied for 30 min each at 22uC. The immunoper-
oxidase reaction was visualized by incubating sections in 0.1%
(wt/vol) 3,39-diaminobenzidine and 0.03% hydrogen peroxide.
The antisera and PAP complex were diluted in TPS buffer
containing 0.25% Triton X-100 and 0.7% (wt/vol) l-carrageenan.
Controls for the immunostaining procedure were prepared by
omission of the first antibody or by the replacement with the
preimmune serum. The sections were rinsed with TPS buffer
between incubations, counterstained with hematoxylin, dehydrat-
ed and cleared with xylene and then coverslipped. The tissue
samples from all of the groups were coded and studied
independently by 2 observers (C.P.V and C.C.) in a blinded
fashion; sections selected at random were used for each animal,
and 3–4 fields per section were studied. Images were acquired
PPARs Regulates Megalin Expression
PLoS ONE | www.plosone.org 14 February 2011 | Volume 6 | Issue 2 | e16794using a Nikon Eclipse E600 microscope and Nikon DXM1200
digital camera. The megalin-stained area in each image was
determined utilizing computer-assisted image analysis software,
Simple PCI (Hamamatsu Co, PA USA). The values corresponding
to total immunostained (brown) cells were averaged and expressed
as the mean absolute values and expressed as squared microns as
described [98]. To evaluate the tubulointerstitial damage in rats,
focus was placed on tubular shape, the presence of protein casts
within the lumens of tubules, cell infiltration in the interstitium and
immunostaining as previously described [98].
Statistical analysis
Data are expressed as means 6 SD of at least three independent
experiments. Comparisons of three or more groups were
performed using ANOVA followed by the Bonferroni test. An
unpaired Student’s t-test was used when two groups were
compared.
Supporting Information
Figure S1 Detection of PPARa, PPARb/d and PPARc in
BN cells by RT-PCR. Expression of the PPAR (a, b and c)
nuclear receptors in the rat yolk sac cell line BN was analyzed by
RT-PCR using different numbers of cycles. The presence of the
PPAR mRNAs in the cell extracts is evident. These expression
levels were compared to those observed in the rat liver (right
panels). In the liver samples, the bands shown correspond to 26
cycles for PPARa, 29 cycles for PPARb and 25 cycles for PPARc.
(TIF)
Figure S2 Mice receiving ciprofibrate and WY 14643
respond to the activation of PPARa but only augment the
expression of megalin at the protein level. BALB/c mice
(n = 3-5/per group) received ciprofibrate (200 mg/kg/day) or
vehicle for 1 week or W Y14643 (50 mg/kg/day) or vehicle for 10
days. (a) The effectiveness of the PPARa agonists was confirmed
by quantification of the mRNA levels of the PPARa target gene
Acox by qPCR. (b) WY 14643 did not affect the expression of
megalin mRNA. (c) Kidney extracts from the animals treated with
WY 14634 were used to determine megalin protein levels by
western blot, with b-tubulin used as loading control. (d) The bands
in the blots were quantified by densitometry, and the results were
plotted as the ratio of megalin/b-tubulin for each condition.
Results are expressed as the mean 6 standard deviation (SD).
Statistically significant differences are indicated by *P , 0.05 vs.
control, **P , 0.01 vs. control.
(TIF)
Figure S3 The expression of megalin is induced by
telmisartan in mouse and rat kidney. BALB/c mice (n = 4-
6/group) and Sprague-Dawley rats (n = 4/group) were treated for
7 or 4 days, respectively, with telmisartan (3 mg/kg/day) or
vehicle. (a) Kidney extracts were used to determine megalin
protein levels in mice, with b-tubulin used as loading control. (b)
The bands in the blots were quantified by densitometry, and the
results were plotted as the ratio of megalin/b-tubulin for each
condition. (c,d) Immunohistochemical detection of megalin
protein in rat kidney sections (cortex) was performed and
quantified. The plots show the megalin staining area (mm
2), which
was significantly increased in the telmisartan group compared to
the control group. Results are expressed as means 6 standard
deviation (SD). Statistically significant differences are indicated as
*P,0.05.
(TIF)
Table S1 Primers for qPCR
(DOC)
Table S2 Probes for EMSA
(DOCX)
Table S3 PPARa and PPARc agonist treatment in mice
(DOCX)
Table S4 Protocol for inducing tubulointerstitial dam-
age and proteinuria in rats; the role of PPARc agonists in
megalin expression
(DOCX)
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